No structural information on U1C protein either in its free state or bound to the spliceosomal U1 small nuclear ribonucleoprotein (snRNP) particle is currently available. Using rabbit antibodies raised against a complete set of 15 U1C overlapping synthetic peptides (16-30 residues long) in different immunochemical tests, linear regions exposed at the surface of free and U1 snRNP-bound U1C were identified. Epitopes within at least three regions spanning residues 31-62, 85-103 and 116-159 were recognized on free and plasticimmobilized recombinant human U1C expressed in Escherichia coli, on in vitro translated U1C protein and on U1C bound to the U1 snRNP particle present in HeLa S100 extract. Using a zinc affinity labeling method, we further showed that the N-terminal U1C peptide containing a zinc-finger motif (peptide 5-34) effectively binds 65 Zn 2+ . The N-terminal region of U1C, which is functional in U1 snRNP assembly, is apparently not located at the surface of the U1 snRNP particle.
INTRODUCTION
The spliceosomal U1, U2, U4/U6 and U5 small nuclear ribonucleoprotein particles (snRNPs) consist of one snRNA molecule (or two in the case of U4/U6) complexed with eight so-called Sm or common proteins (B, B′, D1, D2, D3, E, F and G), which are present in all four spliceosomal snRNPs, and several particle-specific proteins which are specifically associated with one of the spliceosomal snRNPs. Two of the three U1 snRNP-specific proteins, namely U1-70K and U1A, contain a highly conserved RNP motif which is also present in several other RNA binding proteins (1, 2) . This RNP motif is essential for specific binding of U1 snRNA stemloop I by U1-70K (3, 4) and stemloop II by U1A (5) . In contrast, U1C does not contain an RNP motif and can only bind to the U1 snRNP particle when U1-70K and the common proteins are already associated with the U1 snRNA (6) . The N-terminal domain of U1C encompassing a CC-HH zinc-fingerlike region, is necessary and sufficient for U1C binding to the U1 snRNP particle (7) . In addition, part of the zinc-finger-like region (residues [23] [24] [25] [26] [27] [28] [29] [30] ) is suggested to be implicated in the formation of U1C homodimers (8) . Spliceosomal snRNPs are involved in the processing of precursor mRNA (pre-mRNA). In the early steps of spliceosome assembly the U1 snRNP binds the 5′ splice site of pre-mRNA. The U1C protein can augment the binding of U1 snRNP to the 5′ splice site (9) (10) (11) and is important for the formation and/or stabilization of early spliceosomal complexes (12) . Mutagenesis experiments and complementation studies have determined that the N-terminal 60 amino acid residues of U1C are sufficient to enhance the formation of early spliceosomal complexes. This region encompasses a zinc-finger-like structure of the CC-HH type (7) , although this structure has not been shown to be able to bind zinc ions. As a consequence, it is unknown whether U1C adopts a zinc-finger structure. In addition, structural data on the proline-rich C-terminus are also absent. With regard to the constituents of the U1 snRNP particle, only the secondary structure of the N-terminal RNP motif of U1A is known (13, 14) .
The U1 snRNP particle is also the target of auto-antibodies in autoimmune disorders such as systemic lupus erythematosus and mixed connective tissue disease. These auto-antibodies have been used to map epitopes present on the U1-70K, U1A and U1C proteins. In this study, we used rabbit antibodies raised against 15 overlapping U1C synthetic peptides and mapped linear regions exposed on free and snRNP-bound U1C, which allowed us to provide a topographic view of the U1 snRNP molecular assembly. In addition, we showed that peptide 5-34, but not a mutant of this peptide lacking both conserved cysteine residues and one of the two conserved histidine residues, is able to bind Zn 2+ .
MATERIALS AND METHODS

Human U1C expressed in Escherichia coli and synthetic peptides
The recombinant human U1C (rU1C) protein used in this work was overexpressed as a C-terminal (His) 6 -tagged protein in E.coli and purified as described previously (8) . The 15 peptides covering the entire sequence of the human U1C protein were synthesized using Fmoc chemistry (15) . The peptide 5-34 was synthesized because it contains the zinc-finger-like region. A 'mutant' peptide 5-34 was also synthesized in which three of four residues potentially involved in zinc coordination were mutated. This peptide contains the following changes: Cys 6 →Ser, Cys 9 →Ser and His 30 →Ala. All the other peptides span 15-25 amino acid residues. For the latter peptides, the choice of sequences was dictated in part by the presence of Gly-Pro and Pro-Gly sequences because it is rather difficult to start Fmocbased synthesis of a peptide with these sequences at the C-terminus. Homogeneity of all peptides was assessed by analytical HPLC on a nucleosil C18 column, 5 µm (4.6 mm × 150 mm), using a triethylammonium phosphate buffer system. Control peptides 304-324 of the SSA/Ro 60 kDa protein (Ro60), 107-126 of the SSA/Ro 52 kDa protein (Ro52), 103-135 of U1A and 79-92 of histone H3 have been described previously (16) (17) (18) (19) .
Zinc affinity labeling
The effective binding of zinc ions to synthetic peptides containing putative zinc-fingers was tested as described previously (20) using 65 Zn 2+ and peptides immobilized on nitrocellulose. Two peptides known or suspected to bind Zn 2+ (Ro60 peptide 304-324 and Ro52 peptide 107-126 which also contain zincfingers of the CC-HH type) and two peptides which do not contain zinc-finger motifs (peptides 123-144 of U1C and 79-92 of histone H3) were used as positive and negative controls.
Rabbit antisera to U1C peptides
In order to induce anti-peptide antibodies, rabbits were given s.c. inoculations every 2 weeks with unconjugated peptides in the presence of complete Freund's adjuvant for the first and subsequent injections. In the case of peptides 85-103 and 116-133, animals were given s.c. inoculations with ovalbuminconjugated peptides. Conjugation was performed using 1% glutaraldehyde. The final yield of carrier:peptide was 1:17 and 1:14 for peptides 85-103 and 116-133, respectively. The rabbits were bled on a fortnightly basis from the third injection. A prebleeding of each animal was performed and used as control in each assay. Purification of anti-peptide antibodies by affinity chromatography was performed as described previously (21) .
ELISA
ELISA microtitre plates (Falcon, Oxnard, CA; ref. 3912) were coated overnight at 37_C with rU1C (0.1 µg/ml) and U1C synthetic peptides (2 µM) diluted in 0.05 M carbonate buffer pH 9.6. In each assay, antisera were also tested in a non-coated well incubated with coating buffer as a control. The subsequent steps of the test were performed as described previously (22) using anti-rabbit immunoglobulin peroxidase conjugate (Jackson Labs, Bar Harbor, ME; ref. 111-035-003) diluted 1:40 000 in PBS-Tween. The final reaction was visualized by addition of 3,3′,5,5′ tetramethyl benzidine in the presence of H 2 O 2 . To test the surface accessibility of different regions of rU1C, peptides were used as coated antigens and free rU1C as inhibitor of the binding of homologous anti-peptide rabbit antibodies. As a positive control, the homologous peptide was tested in the fluid phase and, as a negative control, peptide 103-135 of U1A was used.
Immunoprecipitation of in vitro translated U1C
Antibodies present in 15 µl of anti-peptide rabbit sera were coupled to protein A-agarose beads (Biozym, Landgraaf, The Netherlands; 20 µl of 50% slurry) and incubated with 1 µl of in vitro translated 35 S-labeled U1C protein produced as described previously (6) , and 500 µl IPP 150 (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Nonidet P-40). The beads were rotated for 2 h at 18_C, washed three times with IPP 150 , resuspended in SDS-PAGE sample buffer, heated for 5 min at 95_C and separated on a 10% SDS-polyacrylamide gel. As a control, 200 µl monoclonal anti-U1A antibodies (9A9: Euro-Diagnostica BV, Arnhem, The Netherlands) or 200 µl monoclonal anti-Sm antibodies (Y12) (23) were coupled to protein A-agarose beads and incubated in the same way.
Immunoprecipitation of U1 snRNPs contained in HeLa S100 extract
Antibodies present in 10 µl of anti-peptide rabbit sera or 4-5 µg affinity-purified anti-peptide antibodies were coupled to protein A-agarose beads (20 µl of 50% slurry) and incubated with 15 µl HeLa S100 extract (extract from 15 × 10 5 cells in 25 mM Tris-HCl pH 7.4, 0.1 mM EDTA, 0.25 mM dithioerythrol, 0.5 mM PMSF, 0.1 M KCl, 0.01% Nonidet P-40, 20% v/v glycerol) and 300 µl IPP 150 . The beads were rotated during 90 min at 18_C, washed three times with IPP 150 , and protein-RNA complexes that were bound to the antibodies coupled to the beads were dissolved in 100 µl IPP 150 /0.5% SDS. RNA was purified by phenol-chloroform extraction followed by ethanol precipitation, and separated on a denaturing 10% polyacrylamide gel. Precipitated RNA was analysed by northern blot hybridization using 32 P-labeled antisense human U1 snRNA as a probe.
RESULTS
The N-terminal region of U1C binds Zn 2+
The U1C protein contains a zinc-finger-like region at its N-terminus, with conserved cysteine residues at positions 6 and 9 and conserved histidine residues at positions 24 and 30. This domain is essential for binding to the U1 snRNP particle (7) and appears to play an important role in the formation of U1C homodimers (8) . However, neither the protein U1C nor shortened U1C fragments have actually been shown to bind Zn 2+ . Because our version of rU1C protein expressed in E.coli contains a C-terminal tag of six histidine residues (8), it was not possible to test the capacity of recombinant human U1C to bind 65 Zn 2+ . We thus used synthetic peptide 5-34 containing the zinc-finger-like region in a previously developed affinity labeling method (20) to test its ability to bind radioactive Zn 2+ . We found that the U1C peptide 5-34 effectively bound 65 Zn ions (Fig. 1) . In contrast, a mutant of peptide 5-34 which contains three amino acid substitutions in the potential zinc-finger motif (namely Cys 6 →Ser, Cys 9 →Ser and His 30 →Ala) was unable to bind 65 Zn 2+ . U1C peptides 1-17 and 25-40 (that do not contain the complete motif) and control peptides 123-144 of U1C and 79-92 of histone H3 did not react with 65 Zn ions (Fig. 1) . Ro60 peptide 304-324 and Ro52 peptide 107-126, which both contain a CC-HH motif, strongly reacted with radioactive Zn 2+ .
From these results we conclude that the N-terminal part of U1C contains a zinc-finger structure that indeed is able to bind Zn 2+ . Next we wanted to determine whether this region of the protein is readily available for protein-protein interactions in the spliceosome.
Three linear regions are exposed on free and U1 snRNP-bound U1C
A series of antisera were raised in rabbits against 15 overlapping U1C synthetic peptides (Table 1 , column 1). The bleedings of each rabbit were first tested using peptide-coated microtitre plates in a direct binding ELISA format (Table 1 , column 2). The specificity of the anti-peptide antibodies was checked using various serum dilutions and various unrelated peptides at different concentrations in direct ELISA, and by a competition ELISA assay using the homologous peptide as antigen and the same or another peptide (i.e. peptide 103-135 of U1A) as competitor ( Table 1, column 3) .
The accessibility of linear regions on U1C protein was then studied using these antibody probes. The 15 anti-peptide antisera were first tested with rU1C directly adsorbed on plastic. In this ELISA format, several peptide antibodies reacted with rU1C protein, namely antibodies induced against peptides 31-48, 44-62, 73-88, 85-103, 97-113, 116-133, 123-144 and 139-159 (Table 1, column 4) . Subsequently, the free protein in solution instead of the immobilized rU1C protein was tested in a competition ELISA. In this assay, rU1C in PBS was used as competitor to inhibit the recognition of coated peptides by their cognate anti-peptide antibodies. Figure 2 shows an example of the reaction with some of the tested U1C peptides (i.e. 25-40, 31-48, 107-127 and 123-144) and the peptide 103-135 of U1A which was used as control. The results demonstrate that residues within Table 1 . Reactivity in ELISA of rabbit anti-U1C peptide antisera with homologous peptides and rU1C
In direct ELISA, rabbit antisera diluted 1:1000 were allowed to react with 0.5 µg/ml rU1C and 2 µM homologous peptide. Absorbance values were measured after substrate hydrolysis time of 15 min and reaction was considered positive when OD 450nm was ≥0.3 in these ELISA conditions: -, OD 450nm < 0.3; +, 0.3-0.75; ++, > 0.75-2.0; +++, > 2.0-3.0. For each peptide, binding of normal rabbit serum was insignificant. Inhibitions by homologous peptides (positive control) and rU1C are expressed as -(<30%) or + (≥30%). Plates were coated with 0.015-0.250 µM of each peptide (depending on each individual peptide). When used as competitors, 0.15-5 µg/ml of each homologous peptide and 0.125-2 µg/ml of rU1C were incubated with rabbit antisera. Depending on rabbit antisera, serum dilution was 1:1000-1:64 000. No inhibition was found with peptide 103-135 of U1A protein used as control (not shown).
the regions spanning residues 31-55, 85-103 and 107-144 are clearly accessible at the surface of free rU1C (Table 1, 
column 5).
To see if similar results could be obtained with in vitro translated U1C, we performed immunoprecipitations with the anti-peptide sera and in vitro translated 35 S-labeled U1C (Fig. 3) . Six of the tested sera (namely antisera to peptides 31-48, 44-62, 85-103, 116-133, 123-144 and 139-159) precipitated the 35 S-labeled U1C very efficiently. These data are very similar to those obtained with rU1C tested in a direct and a competitive ELISA (Table 1, 
columns 4 and 5).
Finally, the same set of anti-peptide sera was used to study the accessibility of the U1C protein contained in the U1 snRNP particle in HeLa S100 extract via detection of precipitated U1 snRNA (Fig. 4) . A number of experiments were also performed with affinity-purified anti-peptide antibodies to confirm the results obtained with anti-peptide sera. The same antibodies that precipitated the in vitro translated 35 S-labeled U1C efficiently also precipitated U1 snRNP from HeLa S100 extract suggesting that a very similar conformational form of U1C is present in the U1 snRNP particle (see Fig. 4 , lanes 4, 6, 10 and 13-15 for antisera to peptides 31-48, 44-62, 85-103, 116-133, 123-144 and 139-159, respectively). Anti-U1A and anti-Sm monoclonal antibodies were used as positive controls (lanes 16 and 17) . Interestingly, differences in precipitation efficiency were observed. For example, antibodies raised against peptide 123-144, which precipitated 35 S-U1C very efficiently, precipitated only small amounts of U1 snRNP (compare Fig. 3, lane 15 with Fig. 4,  lane 14) . A very weak U1 snRNP precipitation was observed with antibodies to peptide 107-127 (Fig. 4, lane 12) ; this reaction was not confirmed using affinity-purified antibodies. The weak reaction observed with antibody to peptide 57-76 is considered as not significant.
From these results, it is likely to assume that the N-terminal part of U1C is anchored and thus buried in the particle. This region is probably not involved in spliceosomal interactions, or in interactions with protein(s) from other nuclear particles. In contrast, three other regions of the U1C protein (31-62, 85-103 and 116-159) are at the surface of the U1 snRNP particle and thus potentially available for particle-particle interactions via their protein moieties.
DISCUSSION
Antibodies directed against defined regions of snRNP molecules certainly represent one of the most valuable probes for studying the topography and conformational changes of the spliceosomal U1 snRNP particles. This approach, in combination with competition assays in which peptides are used as coated antigens and the free cognate U1C protein as inhibitor in the fluid phase, was applied to identify surface-exposed sequences of U1C. Recently, a similar strategy was used to map linear histone regions exposed at the surface of the nucleosome in solution (24) . It should be noted that the absence of antibody reaction does not necessarily mean that the peptide region is not exposed because the peptide segment in the protein and/or particle might have a conformation that is different from the one it adopts when used to immunize animals.
The list of linear U1C regions exposed at the surface of the free protein (rU1C and in vitro translated 35 S-labeled U1C) and on the U1 snRNP particle present in HeLa S100 extract is presented in Table 2 . Residues within at least three regions, namely 31-62, 85-103 and 116-159 were found to be accessible to the anti-peptide antibodies in the different assays used, although some differences in the extent of apparent accessibility were observed. This concerns residues within the regions 73-88 and 97-113, which were accessible to anti-peptide antibodies on plastic adsorbed rU1C only, and 40-55 and 107-127, which were accessible to antibodies on rU1C in solution only. Residues within regions 44-62 and 139-159 were accessible to specific antibodies in all assays except when rU1C was used in solution. These differences can be the consequence of the somewhat denatured form of rU1C, the type and sensitivity of the used assays or the fact that rU1C was expressed in bacteria while 35 S-labeled U1C was expressed in an in vitro system. Immunoprecipitation studies of in vitro translated U1C and U1 snRNP particles using the anti-peptide sera indicated that the same residues are accessible on free and U1 snRNP-bound U1C. Residues within the region 123-144 were significantly less Figure 3 accessible when the U1C protein is bound to the U1 snRNP particle than when it is unbound (compare Figs 3 and 4) . This finding might be the consequence of a conformational change of the protein upon binding to the U1 snRNP particle or result from the fact that this region is involved in protein-protein interactions when U1C is bound to the U1 snRNP particle. Although we cannot exclude the possibility that due to the preparation procedure, some free native U1C is present in HeLa S100 extract which might compete with the bound U1C for binding of anti-peptide antibodies, our results do point to a preferential binding of the anti-peptide antibodies to some regions within U1C and support the conclusion that at least three domains spanning residues 31-62, 85-103 and 116-159 are at the surface of the free and U1 snRNP-bound U1C.
It is noteworthy that the N-terminal domain of U1C is apparently not located at the surface of free and bound protein. This finding reinforces our previous conclusion that U1C protein is able to homodimerize via its zinc-finger-like region and that this complex is needed for efficient functioning of the U1C protein (8) or that the zinc-finger-like region is buried within the U1 snRNP particle (6) . Using U1C substitution mutants, it was suggested that residues Cys 6 , Cys 9 , His 24 and His 30 are involved in the formation of the zinc-finger-like motif (6) (7) (8) . Our results show that the peptide 5-34 effectively binds radioactive Zn 2+ and thus that the N-terminal region of U1C can act as a genuine zincfinger. The mutant peptide with substitutions at residues 6, 9 and 30 was unable to bind this metal ion and probably has a more open conformation. It is presently unclear what the function of this Zn 2+ -binding capacity of U1C could be. Beside the possible binding of a second U1C protein (8) , it could be involved in protein-protein interactions within the U1 snRNP complex itself (6) . The use of other synthetic mutant peptides, as well as mutant rU1C proteins, should tell us whether the zinc coordination motif may also involve Cys 25 , although it has been shown that Cys 25 is not necessary for either homodimerization or interaction with Figure 5 . Structural model of the U1 snRNP particle [modified from Nelissen et al. (6) ]. The N-terminal domain of U1C, which has the capacity to bind Zn 2+ , is apparently not accessible at the surface of the particle. This region may either interact with other U1 snRNP proteins or it could be involved in the binding of a second U1C protein (6, 8) . At least three regions of U1C are exposed at the surface of the U1 snRNP particle. They span residues 31-62, 85-103 and 116-159.
other U1 snRNP proteins (6, 8) . In addition, Will et al. (12) showed in a functional assay that mutation of residues 28 and 29 abolished the ability of the U1C protein to enhance E-complex formation, while substitution of the cysteine residue at position 25 into a serine had only a minor effect.
Taken together, our results are consistent with the structural model of the U1 snRNP particle described by Nelissen et al. (6) . In this model, it is proposed that the N-terminal region of U1C interacts with U1 snRNP proteins while the C-terminal domain of U1C, as well as the C-terminus of U1-70K and U1A, are free to participate in interactions essential for U1 snRNP function during nuclear pre-mRNA splicing. The modified structural model of the U1 snRNP, initially proposed by Nelissen et al. (6) , is presented in Figure 5 .
In conclusion, this study provides new data on the properties of the N-terminal U1C region with regard to its ability to bind Zn 2+ , and the topography of the U1C protein either free or bound to the U1 snRNP particle. It would be interesting to compare the map of U1 snRNP prepared from phylogenetically distant organisms or from cells in different functional states to define whether the same U1C regions are still exposed. This type of experiment should provide valuable information concerning subtle conformational changes that may occur in protein-protein and protein-RNA interactions in relation to the function of this particle in pre-mRNA splicing. In this type of investigation, anti-peptide antibody probes specific for other constitutive proteins of the U1 snRNP particles should also provide important information.
